Celgene May Bid for Human Genome, Reuters Says
(Corrects to say second bidder will propose merger of equals in second paragraph)
Celgene Corp. (CELG) is one of two companies other than GlaxoSmithKline Plc (GSK) weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.
A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.
To contact the reporter on this story: Makiko Kitamura in London at firstname.lastname@example.org
To contact the editor responsible for this story: Dick Schumacher at email@example.com